The FDA approved talazoparib plus enzalutamide for HRR-positive, metastatic androgen pathway modulation–naive or -sensitive prostate cancer.

The FDA has granted traditional approval to pembrolizumab for unresectable/metastatic TMB-H solid tumors.

The FDA has approved dostarlimab for MSI-H or dMMR locally advanced rectal cancer.